Skip to main content

Advantage Alpha Capital Partners LP

SEC CIK
0001762344
Latest filing
Jan 22, 2026

The latest 13F from Advantage Alpha Capital Partners LP covers Q4 2025 (filed Jan 22, 2026) and reports no long positions. Livermore has 20 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q4 2025

Share counts compared with Q3 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
0
Sold out
130
Est. −$331.9M

Top 5 holdings

Share of this quarter's portfolio value

This filing reports no long positions.

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. FTAIFTAI Aviation Ltd.
    −$10.0MSold outHistory
  2. AVDXAvidXchange Holdings, Inc.
    −$6.82MSold outHistory
  3. ZETAZeta Global Holdings Corp.
    −$6.21MSold outHistory
  4. PRVAPrivia Health Group, Inc.
    −$6.00MSold outHistory
  5. CECOCeco Environmental Corp
    −$5.82MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. FTAIFTAI Aviation Ltd.
    −3.03 pp3.0% → 0.0%History
  2. AVDXAvidXchange Holdings, Inc.
    −2.05 pp2.1% → 0.0%History
  3. ZETAZeta Global Holdings Corp.
    −1.87 pp1.9% → 0.0%History
  4. PRVAPrivia Health Group, Inc.
    −1.81 pp1.8% → 0.0%History
  5. CECOCeco Environmental Corp
    −1.75 pp1.8% → 0.0%History

Metrics

13F metrics for Q4 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$0
−$331.9M (−100.0%) vs. prior quarter
Positions
0
−130 vs. prior quarter
Top 10 concentration
–
Top 10 as share of value
Turnover
0.0%
Q4 2025, one quarter
Average holding period
–
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

20 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $701.5M (Q4 2021)

Q1 2021: $475.4MQ2 2021: $518.9MQ3 2021: $548.5MQ4 2021: $701.5MQ1 2022: $668.4MQ2 2022: $579.3MQ3 2022: $544.0MQ4 2022: $470.3MQ1 2023: $480.1MQ2 2023: $500.1MQ3 2023: $476.0MQ4 2023: $528.3MQ1 2024: $531.7MQ2 2024: $458.2MQ3 2024: $439.4MQ4 2024: $423.5MQ1 2025: $408.3MQ2 2025: $371.0MQ3 2025: $331.9M
Q1 2021Q4 2025
13F filings of Advantage Alpha Capital Partners LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q4 2025Jan 22, 20260$0–vs. Q3 2025SEC
Q3 2025Nov 12, 2025130$331.9MFTAIAVDXZETAvs. Q2 2025SEC
Q2 2025Aug 13, 2025119$371.0MFTAIMGNICECOvs. Q1 2025SEC
Q1 2025May 14, 2025146$408.3MFTAIZETAPRMBvs. Q4 2024SEC
Q4 2024Feb 11, 2025153$423.5MAVDXGTLSBFAMvs. Q3 2024SEC
Q3 2024Nov 13, 2024166$439.4MHUBSAPGWMSvs. Q2 2024SEC
Q2 2024Aug 13, 2024154$458.2MLKQSNHQYvs. Q1 2024SEC
Q1 2024May 13, 2024158$531.7MWCCGMSMIDDvs. Q4 2023SEC
Q4 2023Feb 13, 2024154$528.3MMIDDWCCWSCvs. Q3 2023SEC
Q3 2023Nov 14, 202393$476.0MLKQFCFSWCCvs. Q2 2023SEC
Q2 2023Aug 14, 202387$500.1MMIDDFCFSWCCvs. Q1 2023SEC
Q1 2023May 12, 2023115$480.1MFCFSHUBSEHCvs. Q4 2022SEC
Q4 2022Feb 14, 202394$470.3MFCFSEHCState Street SPDR S&P Biotech ETFvs. Q3 2022SEC
Q3 2022Nov 14, 202289$544.0MFCFSROADSTVNvs. Q2 2022SEC
Q2 2022Aug 12, 2022115$579.3MBFAMROADDARvs. Q1 2022SEC
Q1 2022May 16, 2022126$668.4MDARCOUPUNVRvs. Q4 2021SEC
Q4 2021Feb 14, 2022130$701.5MCOUPNATIMIDDvs. Q3 2021SEC
Q3 2021Nov 15, 2021132$548.5MCOUPEVBGURIvs. Q2 2021SEC
Q2 2021Aug 16, 2021131$518.9MCOUPEVBGSLMvs. Q1 2021SEC
Q1 2021May 13, 2021130$475.4MCOUPEVBGSLM–SEC